Contraindicated (1)bortezomib will boost the stage or outcome of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may possibly maximize mavacamten systemic publicity, causing coronary heart failure because of systolic dysfunction. Tell your medical doctor For anyone who is pregnant or prepare to be pregnant. https://dapiosedericate90112.blog-gold.com/32878983/not-known-factual-statements-about-lenvatinib